This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%

This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5%
Rhythm Pharmaceuticals saw a 14.5% surge after its obesity drug, setmelanotide, succeeded in a Phase 3 trial for treating rare conditions. Analysts predict a potential 2035% rally and price target upgrades.